Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients

<p>Abstract</p> <p>Background</p> <p>Malignant gliomas are lethal cancers, highly dependent on angiogenesis and treatment options and prognosis still remain poor for patients with recurrent glioblastoma multiforme (GBM). Ephs and ephrins have many well-defined functions during embryonic development of central nervous system such as axon mapping, neural crest cell migration, hindbrain segmentation and synapse formation as well as physiological and abnormal angiogenesis. Accumulating evidence indicates that Eph and ephrins are frequently overexpressed in different tumor types including GBM. However, their role in tumorigenesis remains controversial, as both tumor growth promoter and suppressor potential have been ascribed to Eph and ephrins while the function of EphA7 in GBM pathogenesis remains largely unknown.</p> <p>Methods</p> <p>In this study, we investigated the immunohistochemical expression of EphA7 in a series of 32 primary and recurrent GBM and correlated it with clinical pathological parameters and patient outcome. In addition, intratumor microvascular density (MVD) was quantified by immunostaining for endothelial cell marker von Willebrand factor (vWF).</p> <p>Results</p> <p>Overexpression of EphA7 protein was predictive of the adverse outcome in GBM patients, independent of MVD expression (p = 0.02). Moreover, high density of MVD as well as higher EphA7 expression predicted the disease outcome more accurately than EphA7 variable alone (p = 0.01). There was no correlation between MVD and overall survival or recurrence-free survival (p > 0.05). However, a statistically significant correlation between lower MVD and tumor recurrence was observed (p = 0.003).</p> <p>Conclusion</p> <p>The immunohistochemical assessment of tissue EphA7 provides important prognostic information in GBM and would justify its use as surrogate marker to screen patients for tyrosine kinase inhibitor therapy.</p

Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients-0

G in both tumor cells and endothelial cells (B). MVD in GBM by immunohistochemical staining for vWF, microvessels are represented by brown clusters, which stand out sharply from other tissues. Low tumor vascularity (C) in GBM with low expression of EphA7 as shown A. In contrast, microvessel density was relatively high (D) in GBM with high expression of EphA7 as shown B. Negative staining in normal brain tissue (E). Original magnification, ×400 (A, B, E) and ×200 (C, D).<p><b>Copyright information:</b></p><p>Taken from "Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients"</p><p>http://www.biomedcentral.com/1471-2407/8/79</p><p>BMC Cancer 2008;8():79-79.</p><p>Published online 25 Mar 2008</p><p>PMCID:PMC2292196.</p><p></p